Cyclic Peptide Mimetics for Amyloid Fibril Binding and Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Amyloidogenic diseases, such as Alzheimer's, Parkinson's, and Huntington's, are characterized by the aggregation of normally soluble proteins into insoluble fibrils, which are resistant to metabolic degradation and contribute to progressive disorders with high morbidity and mortality, and existing treatments lack effective methods to target and destabilize these fibrils.
Innovation Solution
Synthetic cyclic peptide mimetics composed of alternating D- and L-amino acids, including aza- and azasulfuryl-amino acids, are developed, which can be conjugated to agents like chelating groups or nanoparticles for diagnosis and treatment, potentially destabilizing amyloidogenic protein aggregates by increasing hydrogen bonding interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments and diagnostic methods are used for amyloidogenic diseases, then existing therapeutic approaches can be applied, but they are inadequate in effectively targeting and managing amyloid fibrils due to their resistant nature and similar structural properties
Solution Approach 1:
The patent employs parameter changes by systematically varying the amino acid composition, sequence, and stereochemistry (D/L configurations) of cyclic peptide mimetics to optimize their binding affinity and selectivity for amyloid fibrils. This allows the peptides to effectively target the resistant cross-β sheet structure while maintaining adaptability across different amyloid diseases through parameter optimization rather than structural redesign
Solution Approach 2:
The invention creates composite structures by combining cyclic peptide mimetics with imaging agents (fluorophores, paramagnetic complexes) or therapeutic moieties to form multifunctional conjugates. This composite approach enables simultaneous targeting of amyloid fibrils with enhanced reliability while maintaining versatility through modular design that can be adapted to different disease contexts
2Reliability
If cyclic peptide mimetics are designed with alternating D-amino acids and L-amino acids to improve binding activity, then amyloid beta binding activity increases, but the structural complexity and manufacturing difficulty increase
Solution Approach 1:
The synthesis of cyclic peptide mimetics with alternating D/L amino acids is achieved through segmentation of the synthesis process into modular steps using standard solid-phase peptide synthesis (SPPS) techniques. Each amino acid residue can be sequentially added using established protocols, and the cyclic structure is formed through head-to-tail cyclization. This segmented approach breaks down the complex synthesis into manageable stages, making the manufacturing process more feasible despite the stereochemical complexity
Solution Approach 2:
The patent uses aza-amino acid residues as structural copies or analogs of natural amino acids that simplify certain aspects of synthesis while maintaining the desired three-dimensional structure and binding activity. These isosteric replacements can be incorporated using modified but still standardized synthesis protocols, reducing overall manufacturing complexity while preserving the alternating D/L configuration needed for high binding affinity
3Measurement precision
If cyclic peptide mimetics are conjugated with chelating agents or nanoparticles for enhanced imaging capabilities, then diagnostic ability improves, but the device complexity and conjugation requirements increase
Solution Approach 1:
The cyclic peptide mimetics serve as intermediary molecules that bridge the gap between amyloid fibril targets and imaging detection systems. The peptides themselves are relatively simple cyclic structures that can be synthesized using standard protocols, and their role as intermediaries allows coupling to various imaging agents without requiring complex redesign of the core targeting moiety. This intermediary function maintains relative simplicity while enabling enhanced imaging capabilities
Solution Approach 2:
The invention employs universal coupling strategies where the cyclic peptide mimetics are designed with standardized functional groups or attachment points that can conjugate to multiple different types of imaging agents (fluorophores, paramagnetic complexes, radiolabels) or therapeutic moieties. This universal design approach allows a single peptide core structure to be used across multiple applications, reducing overall device complexity through modular, multi-functional conjugates rather than requiring unique complex structures for each application
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclic peptide mimetics demonstrate enhanced amyloid beta binding activity, offering therapeutic and diagnostic potential for amyloid diseases by destabilizing amyloidogenic aggregates and improving imaging capabilities.
Implementation Method 1
The cyclic peptide mimetics demonstrate increased amyloid beta binding activity
Implementation Method 2
The agent may be, for example, a chelating group to bind to a metal or an ion in a conjugate
Implementation Method 3
The agent may be also a thiol to bind a nanoparticle such as gold or iron nanoparticles
Data Source
AI summary
Described herein are synthetic cyclic peptide mimetics comprising alternating D-amino acids and L-amino acids and amino acid derivatives, such as aza-amino acids and azasulfuryl-amino acids. Optionally, the cyclic peptide mimetics may be conjugated to another agent via a linker to form cyclic peptide mimetic conjugates. The cyclic peptide mimetics described herein may be used as diagnostic or therapeutic agents for diagnosis or treatment of amyloidogenic diseases.